Goldman Sachs Group Inc Bellus Health Inc. Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$7.14 - $8.53 $4.75 Million - $5.67 Million	-665,207 Reduced 8.23%	7,413,933 $53.4 Million
Q1 2023 May 11, 2023	SELL	$7.14 - $8.53 $4.75 Million - $5.67 Million	-665,207 Reduced 8.23%	7,413,933 $53.4 Million
Q4 2022 May 14, 2024	BUY	$8.22 - $10.76 $7.25 Million - $9.49 Million	882,090 Added 12.26%	8,079,140 $66.4 Million
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $7.25 Million - $9.49 Million	882,090 Added 12.26%	8,079,140 $66.4 Million
Q3 2022 May 14, 2024	BUY	$8.95 - $12.0 $7.38 Million - $9.89 Million	824,082 Added 12.93%	7,197,050 $76 Million
Q3 2022 Nov 10, 2022	BUY	$8.95 - $12.0 $7.38 Million - $9.89 Million	824,082 Added 12.93%	7,197,050 $76 Million
Q2 2022 May 14, 2024	BUY	$6.46 - $10.02 $41.2 Million - $63.9 Million	6,372,968 New	6,372,968 $58.9 Million
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $309,440 - $479,968	47,901 Added 0.76%	6,372,968 $58.9 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $34.4 Million - $49.4 Million	6,181,546 Added 4307.07%	6,325,067 $43.5 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $754,920 - $1.19 Million	143,521 New	143,521 $1.16 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.